Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: an equilibrium approach

The cerebral A(1) adenosine receptor (A(1)AR) has recently become accessible for in vivo imaging using the selective A(1)AR ligand [(18)F]CPFPX and PET. For broad application in neurosciences, imaging at distribution equilibrium is advantageous to quantify stimulus-dependent changes in receptor availability and to avoid arterial blood sampling. Here we propose a bolus/infusion (B/I) protocol to assess the total distribution volume (DV(t)) of [(18)F]CPFPX under equilibrium conditions. Employing a bolus-to-infusion ratio of 0.8 h, (near) equilibrium conditions were attained within 60 min. The regional DV(t)' given by arterial and venous equilibrium analyses agreed well with conventional two-tissue compartment model analyses (r(2) > 0.94 and r(2) > 0.84, respectively) and Logan's graphical analyses (r(2) = 1.0 and r(2) > 0.93, respectively) (n = 4 healthy volunteers). The mean regional DV(t)' values of these equilibrium analyses and of venous equilibrium analyses in additional seven volunteers demonstrated excellent agreement with the results of earlier bolus studies (r(2) > 0.98). Error simulations show that minor deviations from true equilibrium are associated with negligible to small DV(t) errors. In conclusion, [(18)F]CPFPX shows suitable characteristics for A(1)AR quantification by B/I PET scanning. Carefully standardized venous equilibrium analyses may substitute arterial analyses and thus considerably enhance applicability of A(1)AR PET in clinical routine.

[1]  W C Eckelman,et al.  Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Christer Halldin,et al.  PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.

[3]  R Joeres,et al.  Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis , 1988, Hepatology.

[4]  John W. Daly,et al.  Chronic Effects of Xanthines on Levels of Central Receptors in Mice , 1999, Cellular and Molecular Neurobiology.

[5]  Christian Boy,et al.  Quantification of Cerebral A1 Adenosine Receptors in Humans using [18F]CPFPX and PET , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  S. Rössner,et al.  Removal of exogenous triglycerides in human forearm muscle and subcutaneous tissue. , 2009, Acta medica Scandinavica.

[7]  C. Cotman,et al.  Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in alzheimer hippocampus: A quantitative autoradiographic study , 1993, Neuroscience.

[8]  R. Lewis,et al.  A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). , 1998, Journal of medicinal chemistry.

[9]  P B Hoffer,et al.  In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. , 1994, European journal of pharmacology.

[10]  U Pietrzyk,et al.  An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Dirk Bier,et al.  Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.

[12]  D L Alexoff,et al.  A Strategy for Removing the Bias in the Graphical Analysis Method , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  U. Fuhr,et al.  Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.

[14]  S. Haber,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  D. Charney,et al.  PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  Doris J. Doudet,et al.  In Vivo Receptor Assay with Multiple Ligand Concentrations: An Equilibrium Approach , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  F. Berthou,et al.  Caffeine increases its own metabolism through cytochrome P4501A induction in rats. , 1995, Life sciences.

[18]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  Horst Halling,et al.  Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  T. Porkka-Heiskanen,et al.  Adenosine and sleep. , 2002, Sleep medicine reviews.

[21]  R. Faull,et al.  Loss of A1 adenosine receptors in human temporal lobe epilepsy , 1996, Brain Research.

[22]  P B Hoffer,et al.  Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil. , 1993, European journal of pharmacology.

[23]  C. Alm,et al.  Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. , 2000, Therapeutic drug monitoring.

[24]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[25]  Robert B. Innis,et al.  Kinetic and equilibrium analyses of [123I]epidepride binding to striatal and extrastriatal dopamine D2 receptors , 1999 .

[26]  J. Fritschy,et al.  Seizure Suppression by Adenosine A1 Receptor Activation in a Mouse Model of Pharmacoresistant Epilepsy , 2003, Epilepsia.

[27]  G Blomqvist,et al.  Comparison of the Transient Equilibrium and Continuous Infusion Method for Quantitative PET Analysis of [11C]Raclopride Binding , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[29]  R. Cunha,et al.  Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors , 2001, Neurochemistry International.

[30]  D E Kuhl,et al.  Equilibrium versus Compartmental Analysis for Assessment of the Vesicular Monoamine Transporter Using (+)-α-[11C]Dihydrotetrabenazine (DTBZ) and Positron Emission Tomography , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  V. Ramkumar,et al.  Adenosine, oxidative stress and cytoprotection. , 2001, Japanese journal of pharmacology.

[32]  R. Carson,et al.  PET physiological measurements using constant infusion. , 2000, Nuclear medicine and biology.

[33]  Lutz Tellmann,et al.  In vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  Gilles Tamagnan,et al.  Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380 , 2003, Synapse.

[35]  Gerhard Ransmayr,et al.  Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity , 1998, Neuroscience Letters.

[36]  R Kawashima,et al.  Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  J. A. Carrillo,et al.  Clinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications , 2000, Clinical pharmacokinetics.

[38]  Chang-Shin Park,et al.  Effect of age and smoking on in vivo CYP1A2, flavin‐containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism , 2000, Clinical pharmacology and therapeutics.

[39]  M Slifstein,et al.  Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  W C Eckelman,et al.  Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  H G Mandel,et al.  Update on caffeine consumption, disposition and action. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[42]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[43]  J W Jefferson,et al.  Drug and diet interactions: avoiding therapeutic paralysis. , 1998, The Journal of clinical psychiatry.

[44]  Karl Zilles,et al.  In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography , 2003, NeuroImage.

[45]  Claus Svarer,et al.  Quantification of 5-HT2A Receptors in the Human Brain Using [18F]Altanserin-PET and the Bolus/Infusion Approach , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  Roger N Gunn,et al.  A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261. , 2004, Nuclear medicine and biology.

[47]  C Burger,et al.  Requirements and implementation of a flexible kinetic modeling tool. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[49]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[50]  Anne Constable,et al.  The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats. , 2003, Chemico-biological interactions.

[51]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[52]  Robert B. Innis,et al.  SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[53]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .

[54]  J. Seibyl,et al.  SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  M Fujita,et al.  Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. , 2000, European journal of pharmacology.

[56]  Helmut L. Haas,et al.  Functions of neuronal adenosine receptors , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.